Прямые оральные антикоагулянты: ПЕРВАЯ «ПОДУШКА БЕЗОПАСНОСТИ»
https://doi.org/10.21518/2079-701X-2019-5-6-12
Аннотация
Об авторах
А. А. СоколоваРоссия
Соколова Анастасия Андреевна – к.м.н., ассистент кафедры факультетской терапии №1 лечебного факультета.
119991, Москва, ул. Трубецкая, 8, стр. 2.
А. И. Скрипка
Россия
Скрипка Алена Игоревна – аспирант кафедры факультетской терапии №1 лечебного факультета.
119991, Москва, ул. Трубецкая, 8, стр. 2.
Список литературы
1. 2018 EHRA/ Executive summary. Europace. 2018;20(1).
2. Connolly S.J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51.
3. Eikelboom J. et al; Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. British Journal of Anaesthesia. 2018;120(4):645–656.
4. Fordyce C.B. et al. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Circulation 2016;134(1):37-47.
5. Graham D.J. et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157-64.
6. Graham D.J. et al., Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med. 2016;176(11):1662-1671.
7. Hijazi Z. et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2016;1(4):451-60.
8. Huisman M.V. et al. Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry. Am Heart J. 2018;198:55-63.
9. Kirchhof P. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016;37(38):2893–2962.
10. Larsen T.B. et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.
11. Pollack C.V. Evidence supporting idarucizumab for the reversal of dabigatran. American Journal of Emergency Medicine. 2016;34:33–38.
12. Pollack C.V., Jr., Reilly P.A., van Ryn J, et al. Idarucizumab for Dabigatran Reversal – Full Cohort Analysis. The New England journal of medicine. 2017;377:431-41.
13. Seeger J.D. et al. Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin. Drug Saf. 2017;40(2):169-181.
14. Villines T.C. et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost. 2015;114(6):1290-8.
15. Ревишвили А.Ш., Шляхто Е.В., Замятин М.Н. и соавт. Особенности оказания экстренной и неотложной медицинской помощи пациентам, получающим прямые оральные антикоагулянты: согласительный документ междисциплинарной группы экспертов. Вестник аритмологии. 2018;92:59-72.
Рецензия
Для цитирования:
Соколова А.А., Скрипка А.И. Прямые оральные антикоагулянты: ПЕРВАЯ «ПОДУШКА БЕЗОПАСНОСТИ». Медицинский Совет. 2019;(5):6-12. https://doi.org/10.21518/2079-701X-2019-5-6-12
For citation:
Sokolova A.N., Skripka A.I. Direct oral anticoagulants: first airbag. Meditsinskiy sovet = Medical Council. 2019;(5):6-12. (In Russ.) https://doi.org/10.21518/2079-701X-2019-5-6-12